Analysts’ Opinions Are Mixed on These Healthcare Stocks: IQVIA Holdings (IQV), Ocular Therapeutix (OCUL) and Arrowhead Pharmaceuticals (ARWR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on IQVIA Holdings (IQV – Research Report), Ocular Therapeutix (OCUL – Research Report) and Arrowhead Pharmaceuticals (ARWR – Research Report).
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
IQVIA Holdings (IQV)
Bank of America Securities analyst Michael Ryskin reiterated a Buy rating on IQVIA Holdings yesterday and set a price target of $245.00. The company’s shares closed last Thursday at $180.96, close to its 52-week low of $176.03.
According to TipRanks.com, Ryskin is a 4-star analyst with an average return of
IQVIA Holdings has an analyst consensus of Moderate Buy, with a price target consensus of $253.64, representing a 26.9% upside. In a report issued on February 3, BMO Capital also maintained a Buy rating on the stock with a $260.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Ocular Therapeutix (OCUL)
Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on Ocular Therapeutix yesterday and set a price target of $24.00. The company’s shares closed last Thursday at $8.91.
According to TipRanks.com, Ahmad is a 4-star analyst with an average return of
Ocular Therapeutix has an analyst consensus of Strong Buy, with a price target consensus of $23.86, representing a 169.6% upside. In a report issued on January 21, Piper Sandler also maintained a Buy rating on the stock with a $31.00 price target.
Arrowhead Pharmaceuticals (ARWR)
Morgan Stanley analyst Michael Ulz maintained a Hold rating on Arrowhead Pharmaceuticals today and set a price target of $78.00. The company’s shares closed last Thursday at $64.64.
According to TipRanks.com, Ulz is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Arrowhead Pharmaceuticals with a $82.00 average price target, implying a 22.4% upside from current levels. In a report issued on February 4, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $77.00 price target.
